Our department has a long history of comprehensive development of medical treatment, teaching and research. and now has 7 comprehensive hematology wards with 300 beds including 66 sterile transplantation chambers. It is one of the largest transplantation and cellular therapy centers in China. The center has successfully performed more than 4,000 hematopoietic cell transplants (HCTs) and 65% of which are haploidentical HCTs, achieving outstanding therapeutic effects. The department is one of the leading centers in China to perform cellular immunotherapy (e.g CAR-T, CAR-NK etc) for the treatment of various T/B/myeloid malignant hematologic diseases. The related researches were published in New England Journal of Medicine, Nature, JAMA Oncology, Lancet Haematology, etc. The department established the multiple myeloma treatment center in 2008, which is currently the top-ranked subspecialty center for myeloma and lymphoma in China, and has developed a precise treatment strategy for multiple myeloma and lymphoma. The leukemia team of the department performs accurate diagnosis, clinical prognostic staging and precise treatments for leukemia based state-of-art techniques.

1.  Hematopoietic Stem Cell Transplant Division

The Center has successfully performed more than 4,000 hematopoietic stem cell transplants (HSCT) since it started allogeneic hematopoietic stem cell transplants in the early 1990s, and has constructed a novel comprehensive system of unrelated and haploidentical related hematopoietic stem cell transplants with Chinese characteristics. Being one of the largest and best hematopoietic stem cell transplantation centers in China and all over the world, we perform more than 600 transplantations each year, and 65% of which are haploidentical hematopoietic cell transplantation. The center won the 2nd prize of National Science and Technology Progress Award in 2003 and 2015 for "Clinical Research on Unrelated Allogeneic Hematopoietic Stem Cell Transplantation" and "Key Technological Innovation and Clinical Application of Allogeneic Hematopoietic Stem Cell Transplantation" respectively. In recent years, we have made significant breakthroughs in targeted immunotherapy combined with transplantation for relapsed and refractory acute leukemia and transplantation in elderly patients. We extend the donor selection for HSCT by using the non-first-degree related donors as haploidentical transplant donors. Furthermore, we’ve developed a comprehensive system for preventing and treating GVHD, and various intervention strategies for relapse after HSCT.

2.  Cellular Immunotherapy Division

The center is one of the leading centers in cellular immunotherapy in China and globally. We developed universal CAR-T cells derived from healthy donors, elevating the overall response rate in relapsed/refractory leukemia from 30% with conventional chemotherapy to 82%. We pioneered an innovative “CAR-T bridging hematopoietic stem cell transplantation” strategy (sequential CD19 or CD7 CAR-T followed by transplantation), reducing relapse rates from 67% to 17% and improving overall survival from 20% to 68%. Additionally, we established a chemotherapy-free regimen combining CAR-T with targeted agents for newly diagnosed leukemia, preserving patient T-cell function while enhancing CAR-T cytotoxicity, achieving a 92% 2-year disease-free survival rate and ushering leukemia treatment into a chemotherapy-free era.

We elucidated the immunosuppressive mechanisms of the lymphoma microenvironment, revealing how tumor cells induce CAR-T exhaustion via the metabolic checkpoint IDH2 and exhaustion checkpoint PD-1. We developed non-viral vector-based site-specific PD-1 gene integration technology for scalable CAR-T manufacturing, establishing an efficient clinical translation platform that significantly increased complete remission rates in relapsed/refractory lymphoma from 50% to 87.5%. To address the problem of disease relapse after BCMA CAR-T therapy in multiple myeloma, we originally developed GPRC5D nanobody-based CAR-T cells, achieving a 100% overall response rate in BCMA-negative relapsed patients and providing a breakthrough treatment for end-stage refractory cases.

The project has secured 23 invention patents; developed 8 innovative CAR-T products; conducted 18 pivotal clinical trials; led formulation of 4 Chinese expert consensuses on CAR-T therapy; published 153 papers in journals including NEJM, Nature, JAMA Oncology, and Cell Metabolism; authored China’s first textbooks CAR-T Cell Immunotherapy and 100 Questions on CAR-T Cell Immunotherapy; and received 2 first prizes at provincial/ministerial-level science and technology awards.

3.  Multiple Myeloma and Lymphoma Division

The Center established the Multiple Myeloma Treatment Center in 2008, which is currently the top-ranked subspecialty center for myeloma in China, and has developed a precise and comprehensive treatment strategy for multiple myeloma. The center led and organized more than 30 hospitals in the province to establish the Zhejiang Multiple Myeloma Alliance, integrated the advantages of regional resources and gave full play to the regional medical centers. The center has been awarded the 1st Prize of Science and Technology Progress in Zhejiang Province and the 2nd Prize of Science and Technology Progress in the Research Excellence Award of Higher Education Institutions.

4.  Leukemia Division

The leukemia team of the Center performs accurate diagnosis, clinical prognostic staging and precise treatments for leukemia based on state-of-art techniques. The clinical efficacy has reached a domestic leading and internationally advanced level.

1.      Key Technology Innovation and Application of Allogeneic Stem Cell Transplantation.

National Science and Technology Advancement Award, Second Class, 2015

2.      Clinical Research on Allogeneic Bone Marrow Transplantation.

National Science and Technology Advancement Award, Second Class, 2003

Science and Technology Advancement Award of Zhejiang Province, First Class, 2002

Medicine and Health Technology Innovation Awards of Zhejiang Province, First Class, 2001

3.      Development of novel CAR-T cells and establishment of an innovative clinical translation system for the treatment of malignant hematological diseases.

Science and Technology Advancement Award of Zhejiang Province, First Class, 2023.

4.      Establishment of Key Technologies and Clinical Application of Chimeric Antigen Receptor T cells in Treatment of Hematologic Malignancies.

Chinese Medical Science and Technology Award, Second Class, 2023

Science and Technology Advancement Award of Zhejiang Province, First Class, 2021.

5.      Noval Strategy of Risk-assessment,Prophylaxis and Treatment for Major Complications after Allogeneic Hematopoietic Stem Cell Transplantation.

High School Science and Technology Advancement Award, First Class, 2013.

6.      Foundation and Application of New Risk Stratification Mode for Multiple Myloma .

Science and Technology Advancement Award of Zhejiang Province, First Class, 2013.

7.      The Optimization of Diagnosis and Treatment System for Multiple Myeloma and Research on Drug Resistance Mechanisms, Second Prize of the Higher Education Outstanding Scientific Research Achievement Award, 2020